Effect of hormone replacement therapy with estradiol in frozen embryo transfer on estrogen metabolism in women with various polymorphisms of catechol-O-methyltransferase gene

2021 ◽  
Vol 11_2021 ◽  
pp. 213-220
Author(s):  
Kvashnina E.V. Kvashnina ◽  
Tutakov M.A. Tutakov ◽  
Vakhlova O.S. Vakhlova ◽  
Tomina E.V. Tomina ◽  
Shilova N.V. Shilova ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Embryo Transfer ◽  
Hormone Replacement ◽  
Frozen Embryo Transfer ◽  
Estrogen Metabolism ◽  
Methyltransferase Gene

scholarly journals Serum levels of cancer antigen 125 before hormone replacement therapy are not associated with clinical outcome of frozen embryo transfer in women with adenomyosis

2021 ◽  
Vol 49 (4) ◽  
pp. 030006052110058
Author(s):  
Ling Huang ◽  
Yubin Li ◽  
Minghui Chen ◽  
Zengyan Wang ◽  
Canquan Zhou
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Embryo Transfer ◽  
Operating Characteristic ◽  
Characteristic Curve ◽  
Hormone Replacement ◽  
Frozen Embryo Transfer ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Serum Ca125

Aim This retrospective study aimed to evaluate the predictive value of serum cancer antigen 125 (CA125) levels before hormone replacement therapy on pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer. Methods A total of 509 women with adenomyosis were screened and 84 patients receiving a total of 114 cycles of frozen embryo transfer were included, based on the inclusion and exclusion criteria. Patients were divided into two groups based on their CA125 levels (≤ or >35 IU/mL) before hormone replacement therapy. The basic characteristics and main outcomes of the two groups were compared. Receiver operating characteristic curve and subgroup analyses were also conducted. Results There were no significant differences in clinical outcomes of frozen embryo transfer cycles in patients with different serum CA125 levels before hormone replacement therapy. Receiver operating characteristic curve analysis demonstrated that CA125 levels before hormone replacement therapy were not predictive of clinical pregnancy outcomes. Conclusions Serum CA125 levels before hormone replacement therapy are not associated with the clinical outcomes of frozen embryo transfer among women with adenomyosis.

scholarly journals Effects of artificial cycles with and without gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in patients with adenomyosis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Muzi Li ◽  
Lihong Xu ◽  
Heng Zhao ◽  
Yanbo Du ◽  
Lei Yan
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Embryo Transfer ◽  
Live Birth ◽  
Pregnancy Outcomes ◽  
Hormone Replacement ◽  
Gonadotropin Releasing Hormone ◽  
Clinical Pregnancy ◽  
Frozen Embryo Transfer ◽  
Gonadotropin Releasing Hormone Agonist

AbstractGonadotropin-releasing hormone agonist (GnRH-a) is generally added to the improve pregnancy outcomes of hormone replacement therapy cycles among patients with adenomyosis. We aimed to investigate whether adding GnRH-a can result in better pregnancy outcomes. This retrospective analysis included 341 patients with adenomyosis who underwent frozen embryo transfer (FET) after in vitro fertilization (IVF). The control group was treated only with hormone replacement therapy cycles to prepare the endometrium, and GnRH-a was added to the study group before hormone administration to adjust the menstruation cycle. Based on the similar baseline values and embryological data, there was no significant difference in the clinical pregnancy rates (40.63% vs. 42.54%, P = 0.72) and live birth rates (23.75% vs. 23.75%, P = 0.74) of the control and study groups. Other secondary outcomes, including the rates of clinical miscarriage, ectopic pregnancy, preterm birth and term birth, were not significantly different between the two groups. Compared with the hormone replacement therapy cycle alone, GnRH-a downregulation based on a hormone replacement therapy cycle may not increase the rate of clinical pregnancy or live birth of IVF-ET with FET among infertile patients with adenomyosis.

Maintenance of Pregnancy and Obstetric Outcome in Donor Egg Pregnancies

1992 ◽  
Vol 4 (6) ◽  
pp. 712
Author(s):  
J Leeton ◽  
I Calderon ◽  
J Burden ◽  
K Azuma ◽  
P Renou
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Embryo Transfer ◽  
Vaginal Delivery ◽  
Hormone Replacement ◽  
Embryo Implantation ◽  
Ovarian Failure ◽  
Obstetric Outcome ◽  
Donor Egg ◽  
Monozygous Twins

Data are presented on the outcome of 43 pregnancies between 1983 and 1991. Maintenance of pregnancy in agonadal women begins at the time of embryo implantation, and initial hormone replacement therapy to prime the endometrium before embryo transfer is an important factor. Synchronization in agonadal women is successful with the variable-length oestrogen replacement regime but can be difficult in ovulating recipients. The outcome of donor egg (DE) pregnancies in this study is comparable to that of IVF pregnancies, with the possible exception of an increased rate of monozygous twins. Pre-eclampsia does not appear to increase significantly in DE pregnancies. Vaginal delivery is possible for DE pregnancies in women with ovarian failure.

Sign in / Sign up

Export Citation Format

Share Document